Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary through Q4 earnings and following the recent opportunity it had to catch-up with management on the current status of the pipeline, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals, Enamine release new tools in its AI/ML platform
- Recursion announces first patient dosed in Phase 1 REC-3565 study
- Strategic Positioning and Operational Resilience Justify Buy Rating for Recursion Pharmaceuticals
- Recursion Pharmaceuticals call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment buys 205K shares of Recursion Pharmaceuticals today